THE publication of the Public Accounts Committee (PAC) report on rising health insurance premiums and private hospital charges has brought important attention to medicine pricing and the wider cost of healthcare in Malaysia.
For the local pharmaceutical manufacturing industry, the report provides a constructive basis to consider how Malaysia can improve medicine accessibility and affordability while continuing to strengthen the security and reliability of our medicine supply.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
